EMERGENCY:A patient with elevated phytanic acid and rapid neurological deterioration, or signs of cardiac arrhythmia, requires urgent assessment. Plasma exchange may be needed to rapidly lower phytanic acid levels. —call040-46324365immediately — 24 hours, 7 days— 24/7
Phytanic Acid Storage Disease in Hyderabad: Understanding the Spectrum — From Treatable Refsum Disease to the Broader Zellweger Peroxisomal Disorders
Expert plasma phytanic acid and pristanic acid measurement, VLCFA / pipecolic acid / plasmalogen / bile-acid intermediate metabolic panel, PHYH and PEX gene panels, dietary restriction, DHA and antioxidant supplementation, multidisciplinary supportive care for the Zellweger spectrum, and connection to emerging gene-therapy registries by the KIMS Neuroscience team at KIMS Neuroscience, Secunderabad, Hyderabad.
Phytanic acid storage disease is the umbrella term for inherited peroxisomal disorders in which phytanic acid (a branched-chain fatty acid derived entirely from the diet) accumulates pathologically because the peroxisomal alpha-oxidation pathway is defective. The spectrum includes: (1) classical adult Refsum disease (PHYH or PEX7 mutations, isolated phytanic acid alpha-oxidation deficiency, dietary restriction is genuinely disease-modifying); (2) the Zellweger spectrum disorders (PEX gene mutations affecting peroxisomal biogenesis — Infantile Refsum Disease, Neonatal Adrenoleukodystrophy, classical Zellweger syndrome — with multiple peroxisomal pathways impaired); and (3) rhizomelic chondrodysplasia punctata. The central clinical task when phytanic acid is elevated is to determine which sub-entity is present, because management differs sharply: very long chain fatty acids (VLCFAs) are NORMAL in classical Refsum and ELEVATED in the Zellweger spectrum. KIMS provides the complete peroxisomal biochemical panel (phytanic acid, VLCFA, pipecolic acid, plasmalogens, bile acid intermediates) followed by targeted gene panel testing, dietary counselling for classical Refsum, supportive multidisciplinary care for the Zellweger spectrum, and family genetic counselling.
- VLCFA — part of the biochemical panel, not a stand-alone discriminator
- When plasma phytanic acid is elevated, the next question is whether this is an isolated phytanic acid alpha-oxidation defect (classical Refsum, diet-treatable) or a broader peroxisomal biogenesis defect (Zellweger spectrum, where dietary phytanic acid restriction is far less effective). VLCFA analysis is an important component of biochemical evaluation. Normal VLCFAs support classical adult Refsum disease, whereas elevated VLCFAs suggest a broader peroxisomal disorder such as the Zellweger spectrum. However, VLCFAs should be interpreted together with phytanic acid, plasmalogens, pipecolic acid, bile acid intermediates, clinical phenotype and molecular genetic testing rather than used as a stand-alone diagnostic discriminator.
- Infantile Refsum Disease is a misnomer — it is PEX, not PHYH
- 'Infantile Refsum Disease' (IRD) sounds like an early-onset version of classical Refsum, but it is NOT. IRD is caused by mutations in PEX genes (PEX1, PEX6, others) — the same family of genes responsible for the Zellweger spectrum. IRD is in fact the MILDEST end of the Zellweger spectrum. Multiple peroxisomal pathways are impaired, not just phytanic acid alpha-oxidation. Dietary phytanic acid restriction has PARTIAL benefit only — clinical management differs substantially from classical Refsum.
- Classical (adult) Refsum disease — PHYH or PEX7
- PHYH mutations (commonest) and PEX7 mutations (rarer) produce isolated deficiency of phytanic acid alpha-oxidation. Plasma phytanic acid markedly elevated; other peroxisomal markers normal. Onset typically second or third decade. Dietary restriction genuinely halts and partially reverses neurological features. See the Refsum disease page for full clinical management.
- Zellweger spectrum — the severe end
- Classical Zellweger syndrome (cerebrohepatorenal syndrome): neonatal hypotonia, dysmorphic features (high forehead, large fontanelle, flat face), hepatomegaly, seizures, polycystic kidneys, profound psychomotor delay, death typically within the first year. Neonatal adrenoleukodystrophy and Infantile Refsum Disease occupy the milder end. All caused by PEX gene mutations. Diagnosed on the combination of elevated VLCFA, elevated pipecolic acid, reduced plasmalogens, and abnormal bile acid intermediates.
- The complete peroxisomal panel at KIMS
- When peroxisomal disease is suspected, KIMS sends a complete panel: plasma phytanic acid + plasma VLCFAs (C26:0, C24:0, ratios) + pipecolic acid + erythrocyte plasmalogens + bile acid intermediates. The pattern of abnormalities — not any single marker — distinguishes classical Refsum, Zellweger spectrum (Infantile Refsum, Neonatal ALD, classical Zellweger), and rhizomelic chondrodysplasia punctata. Confirmed biochemically, then by targeted gene panel.
- Why this matters for treatment
- Classical Refsum: phytanic acid-restricted diet genuinely halts progression. Zellweger spectrum: diet is partial-benefit only; supportive care dominates; some sub-phenotypes benefit from docosahexaenoic acid (DHA) supplementation and ursodeoxycholic acid for cholestasis. Getting the biochemical discrimination right BEFORE committing the family to a particular management plan is the central clinical task.
- Rhizomelic chondrodysplasia punctata (RCDP) — the third pattern
- Caused by PEX7 mutations (severe form) or biallelic GNPAT/AGPS mutations. Characterised by rhizomelic shortening of the limbs, calcific stippling of cartilage on radiographs, congenital cataracts, profound developmental delay, and reduced plasmalogen synthesis. Plasma phytanic acid mildly elevated. Important to distinguish from classical Refsum (PEX7 mutations can produce either).
| Fact | Details |
|---|---|
| Definition | Spectrum of inherited disorders with pathological phytanic acid accumulation due to defective peroxisomal alpha-oxidation · Includes classical Refsum, Zellweger spectrum, and rhizomelic chondrodysplasia punctata |
| VLCFA interpretation | Normal VLCFAs support classical adult Refsum; elevated VLCFAs suggest a broader peroxisomal disorder such as Zellweger spectrum · Not a stand-alone discriminator — interpret with phytanic acid, plasmalogens, pipecolic acid, bile acid intermediates, clinical phenotype and molecular genetic testing |
| Classical Refsum (PHYH / PEX7) | Isolated phytanic acid alpha-oxidation deficiency · VLCFA normal · Adolescent/adult onset · Dietary restriction halts disease · See Refsum disease page |
| Zellweger spectrum (PEX genes) | Multiple peroxisomal pathways impaired · VLCFA, pipecolic acid elevated · Plasmalogens reduced · Severity from neonatal lethal (Zellweger) to mild (Infantile Refsum) · Diet partial benefit |
| Infantile Refsum Disease (misnomer) | PEX gene mutations, NOT PHYH · Mild end of Zellweger spectrum · Not the same as classical adult Refsum · Different management |
| Diagnosis at KIMS | Complete peroxisomal panel: phytanic acid + VLCFAs + pipecolic acid + plasmalogens + bile acid intermediates · Targeted gene panel after biochemical pattern established |
| Management | Classical Refsum: phytanic acid-restricted diet (genuine DMT) · Zellweger spectrum: supportive + DHA + ursodeoxycholic acid for cholestasis where indicated · Family genetic counselling |
About This Condition
Phytanic Acid Storage Disease at a Glance
The essential facts that shape how phytanic acid storage disease is recognised, classified, and managed at KIMS — from the biochemistry of phytanic acid alpha-oxidation, to the Zellweger-spectrum peroxisomal-biogenesis connection, the confusingly named infantile Refsum disease, and the diagnostic priority of distinguishing diet-treatable classical Refsum from the broader PEX-gene disorders.
What it is
Phytanic acid storage disease is the clinical and biochemical term for any condition in which phytanic acid — a branched-chain fatty acid derived from dietary phytol (from chlorophyll and ruminant fat) — accumulates abnormally in the body because phytanic acid alpha-oxidation is impaired. The prototype is Refsum disease (PHYH or PEX7 deficiency), described on page 7. However, phytanic acid elevation also occurs in a broader group of peroxisomal biogenesis disorders — the Zellweger spectrum disorders (caused by mutations in PEX genes) — where multiple peroxisomal functions are impaired simultaneously, of which phytanic acid metabolism is only one.
The Zellweger spectrum connection
The Zellweger spectrum disorders (ZSD) range from the severe neonatal Zellweger syndrome (ZS) to the milder neonatal adrenoleukodystrophy (NALD) and the relatively mild infantile Refsum disease (IRD). All ZSD result from mutations in PEX genes (peroxin genes) that are required for peroxisome biogenesis and function. Peroxisomes perform multiple essential metabolic functions including VLCFA beta-oxidation (relevant to ALD), phytanic acid alpha-oxidation, and plasmalogen synthesis. ZSD therefore produce a cluster of metabolic abnormalities: elevated VLCFAs + elevated phytanic acid + elevated pipecolic acid + reduced plasmalogens.
Infantile Refsum disease (IRD) — the mild ZSD end
Infantile Refsum disease (a confusing name — it is caused by PEX gene mutations, not PHYH mutations, and is clinically more severe than classical Refsum disease despite the name) presents in infancy with: hypotonia, developmental delay, retinitis pigmentosa, sensorineural hearing loss, hepatomegaly, and facial dysmorphism. Plasma phytanic acid is elevated alongside VLCFAs. Unlike classical Refsum disease (PHYH), the diet is far less effective because multiple peroxisomal pathways are disrupted.
The diagnostic priority
When plasma phytanic acid is elevated in any patient, the key question is: is this an isolated PHYH/PEX7 deficiency (classical Refsum disease, treatable with diet) or a broader Zellweger spectrum disorder (multiple peroxisomal functions disrupted)? The answer comes from measuring VLCFAs, plasmalogens, and pipecolic acid alongside phytanic acid. If only phytanic acid is elevated and VLCFAs are normal: likely Refsum disease. If VLCFAs are also elevated: likely Zellweger spectrum.
Appointment
040-44885000
Why a Single Elevated Blood Test Has Different Meanings
Plasma phytanic acid is measured at KIMS as part of the workup for any patient presenting with: retinitis pigmentosa + peripheral neuropathy; cerebellar ataxia + neuropathy with elevated CSF protein; or suspected peroxisomal disorder. The result — an elevated plasma phytanic acid — initiates a specific additional investigation cascade, because elevated phytanic acid is the biochemical entry point into two very different diagnostic categories with very different management implications.
Category 1: Classical Refsum disease (PHYH or PEX7 deficiency). The peroxisome is present and functional for all other purposes; only phytanic acid alpha-oxidation is impaired. Plasma VLCFAs are normal. Plasmalogens are normal. Pipecolic acid is normal. Treatment with a phytanic acid-restricted diet is highly effective. The section on Refsum disease (page 7) covers this in full.
Category 2: Zellweger spectrum disorders (PEX gene mutations). The peroxisome itself is absent or severely dysfunctional. Multiple metabolic pathways are simultaneously impaired: VLCFAs are elevated (as in ALD — but caused by absent peroxisomes rather than a specific ALDP deficiency); phytanic acid is elevated; pipecolic acid is elevated; plasmalogens are reduced. The clinical picture is more severe and dietary treatment has limited effect.
Distinguishing these two categories requires the full peroxisomal metabolic panel, which KIMS arranges simultaneously when phytanic acid is elevated.
Book a Consultation
Speak directly with The KIMS Neuroscience team and the KIMS peroxisomal disorder specialist team — neurology, metabolic medicine, ophthalmology, audiology, cardiology, hepatology, endocrinology, and clinical genetics under one roof. Family genetic workup arranged with priority. No referral required. Monday to Saturday.
040-44885000Acute deterioration / arrhythmia: 040-44885000The Zellweger Spectrum — Severity from Neonatal to Adult Disease
Zellweger spectrum disorders (ZSDs) represent a continuum of peroxisomal biogenesis disorders caused by PEX gene mutations. The spectrum ranges from the severe neonatal Zellweger syndrome to milder childhood and adult phenotypes. The clinical severity reflects the degree of global peroxisomal dysfunction and the number of metabolic pathways impaired.
Zellweger syndrome (ZS) — the severe end
The most severe Zellweger spectrum disorder (ZSD). Presents in the neonatal period with profound hypotonia (the infant is profoundly floppy), characteristic facial features (high forehead, large fontanelle, broad nasal bridge), hepatomegaly and liver dysfunction, cortical malformations (neuronal migration defects), and absent or severely reduced peroxisomes on liver biopsy. Severe intellectual disability is typical. Retinitis pigmentosa and sensorineural hearing loss develop in survivors. Most infants with classic ZS die within the first year from respiratory failure or liver failure. Plasma profile: elevated VLCFAs + elevated phytanic acid + elevated pipecolic acid + very low plasmalogens.
Neonatal adrenoleukodystrophy (NALD) — intermediate severity
Presents in the neonatal or early infantile period, less severely than Zellweger syndrome. Facial features are less pronounced. Liver disease is present but less severe. Developmental delay, hypotonia, visual impairment, and hearing impairment occur. Some children survive into childhood or early adulthood. Brain MRI shows white matter changes (leukodystrophy) resulting from multiple peroxisomal pathway failure. VLCFAs and phytanic acid are elevated.
Infantile Refsum disease (IRD) — the mild ZSD end
Despite the name containing “Refsum,” infantile Refsum disease is a PEX gene disorder within the Zellweger spectrum, not a PHYH mutation disorder. Features include hypotonia and developmental delay in infancy, retinitis pigmentosa developing in childhood, sensorineural deafness, and hepatomegaly. Some patients survive into adulthood with moderate intellectual disability. Phytanic acid and VLCFAs are elevated. Diet has partial benefit by reducing phytanic acid exposure, but the broader peroxisomal dysfunction is not diet-correctable.
Adult Refsum disease — classical PHYH deficiency
Classical adult or late-onset Refsum disease presents in the second or third decade with the tetrad: retinitis pigmentosa + peripheral neuropathy + cerebellar ataxia + elevated CSF protein. The peroxisomal defect is limited specifically to phytanic acid alpha-oxidation (PHYH or PEX7 mutation). VLCFAs are normal and plasmalogens are normal. Dietary treatment is dramatically effective. This is the treatable form and requires urgent identification and dietary intervention.
Diagnosis at KIMS
The Peroxisomal Metabolic Panel at KIMS
When plasma phytanic acid is elevated, KIMS simultaneously arranges the full peroxisomal metabolic panel — phytanic and pristanic acids, VLCFAs (the key discriminator), pipecolic acid, plasmalogens, bile acid intermediates — followed by PHYH / PEX7 / PEX-gene panel sequencing to definitively classify the patient as classical Refsum disease or a Zellweger spectrum disorder.
Plasma VLCFAs — the key discriminator
Plasma VLCFAs (C26:0, C26:0/C22:0 ratio): normal in Refsum disease (PHYH/PEX7); elevated in Zellweger spectrum. The VLCFA result is the key discriminator.
Plasma pipecolic acid
Plasma pipecolic acid: elevated in ZSD (accumulates because pipecolic acid oxidation is a peroxisomal function); normal in Refsum disease.
Red blood cell plasmalogens
Red blood cell plasmalogens (plasmalogen synthesis is peroxisomal): reduced in ZSD; normal in Refsum disease.
Plasma phytanic acid and pristanic acid
Plasma phytanic acid AND pristanic acid: both elevated in Refsum and ZSD; the ratio varies.
Plasma bile acid intermediates
Plasma bile acid intermediates: elevated in ZSD from impaired peroxisomal bile acid synthesis.
Genetic testing
Genetic testing: PHYH + PEX7 sequencing for Refsum disease. PEX gene panel (PEX1, PEX2, PEX3, PEX5, PEX6, PEX7, PEX10, PEX12, PEX13, PEX14, PEX16, PEX19, PEX26) for Zellweger spectrum.
Interpretation at KIMS
Elevated phytanic acid + normal VLCFAs + normal pipecolic acid + normal plasmalogens = Refsum disease (PHYH/PEX7). Confirm with gene sequencing. Treat with diet.
Elevated phytanic acid + elevated VLCFAs + elevated pipecolic acid + reduced plasmalogens = Zellweger spectrum disorder (PEX gene). Confirm with PEX gene panel. Management is supportive with dietary modification.
Management by Diagnosis — Refsum Disease vs Zellweger Spectrum
Management at KIMS is matched to the specific diagnosis — dietary phytanic acid restriction that genuinely halts classical Refsum disease, and multidisciplinary supportive care for the Zellweger spectrum disorders where no disease-modifying treatment yet exists.
Diet-treatable Refsum disease vs supportive Zellweger spectrum management
Classical Refsum Disease (PHYH / PEX7) — Dietary Treatment: See page 7 (Refsum Disease) for the complete management protocol. Key points: phytanic acid-restricted diet (eliminate ruminant dairy fat, ghee, lamb, mutton, beef; limit oily fish); plasma phytanic acid monitoring every 3–6 months; plasma exchange for acute crises; cardiology monitoring; ophthalmological monitoring; dietitian support. The diet is lifelong and genuinely halts and partially reverses neurological features.
Zellweger Spectrum Disorders (PEX Gene Mutations): No curative treatment currently exists for ZSD. Management is supportive and multidisciplinary: phytanic acid and VLCFA restriction reduces the dietary substrate load and may slow some aspects of neurological and retinal involvement (less effective than in Refsum disease because peroxisomes are globally dysfunctional and the diet cannot restore peroxisomal function); DHA (docosahexaenoic acid) supplementation has been investigated to partially restore plasmalogen levels (evidence for neurological benefit is limited); antioxidants (vitamin E, coenzyme Q10) used empirically in some centres given oxidative stress in ZSD (no strong evidence for neurological benefit); AEDs for epilepsy, which is common in ZSD; hearing aids for sensorineural hearing loss — important for language development in milder ZSD; annual adrenal function assessment as some ZSD patients develop adrenal insufficiency from the shared peroxisomal pathway for adrenal steroidogenesis; palliative and supportive care for severe ZSD (Zellweger syndrome), focusing on comfort and family support.
Related Conditions
Phytanic acid storage disease belongs to the family of hereditary polyneuropathies and leukodystrophies evaluated and managed at KIMS Neuroscience:
FAQs
Frequently Asked Questions
Elevated phytanic acid means different things depending on what else is abnormal. Classical Refsum disease (diet-treatable) is identified by normal VLCFAs. Zellweger spectrum (supportive management) is identified by elevated VLCFAs + elevated pipecolic acid.
At KIMS Neuroscience, Secunderabad, Hyderabad, the complete peroxisomal metabolic panel makes this distinction at the first assessment. Call 040-44885000 to book a phytanic acid storage disease assessment.
International enquiries: info@kimsneurosciences.com